Carlton South Vic 3053, Australia
Go to Investors Hub
info@radiopharmtheranostics.com
Latest News

Radiopharm Theranostics
Category: Analyst Reports

Capital Raise And Clinical Updates Position RADX to Advance the Pipeline
RAD KOL Webinar on Pivalate
NDR and Webinar Takeaways Along with Upcoming Clinical Data
Multiple Data Readouts on Track for 2H25
FY25 Appendix 4C and Business Update – Multiple Catalysts Approach in 2H25 Across Maturing Radioconjugate Pipeline
Radiopharm Theranostics (NASDAQ: RADX) Initiate with a Buy Rating and $18 Target Price
Our Most Important Update of the Year: FDA Removes “Invisible” Dose Ceiling for RLT, Opening a New Era of RLT Innovation; Reit. Buy on CATX, LNTH, RADX
PDL1 ADC Updates at ASCO25 Read Positively to RADXs PDL1T
Zachs Small-Cap Research RAD Initiating Coverage – Adding a Radio- isotope to Precision Oncology
Think Equity Update May 2025
Categories
Announcements
Announcements
Annual Reports
Annual Reports
Presentations
Presentations
News
News
Recent News
Analyst ReportsAnnouncementsAnnual ReportsInvestor PresentationsRAD ArticlesUpdates
Tags
Tags
Appendix 2A (1) Appendix 3B (1) Change of Director's Interest Notice (1) Cleansing Notice (1) PDF (34) Periodic Reports (25) Price Sensitive (84) Progress Report (2) Video (3) With Summary (2) With Video (4)
Archives
Archives
RSS RSS
Close
Search

Hit enter to search or ESC to close

cookie By using this website, you agree to our cookie policy. Close